Curtailed two-stage matched pairs design in double-arm Phase II clinical trials

Christa Carsten, Pinyuen Chen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This article proposes a curtailed two-stage matched pairs design to shorten the drug development process in Phase II clinical trials for which there are two arms, a treatment arm and a control arm, and the primary goal being to test whether the treatment is significantly better than the control. The design presented in this article uses the inverse trinomial distribution to determine appropriate cutoff points for the termination or continuation of the trial at each stage and is best suited for trials in which there is a low success rate and the available sample size is limited, such as is the case for trials involving rare forms of cancer or other uncommon diseases.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Biopharmaceutical Statistics
DOIs
StateAccepted/In press - Feb 20 2016

Fingerprint

Matched pairs
Phase II Clinical Trials
Clinical Trials
Sample Size
Pharmaceutical Preparations
Neoplasms
Termination
Development Process
Continuation
Cancer
Drugs
Design

Keywords

  • Curtailed two-stage design
  • double-arm
  • expected sample size
  • matched pairs
  • Phase II clinical trial

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Statistics and Probability

Cite this

Curtailed two-stage matched pairs design in double-arm Phase II clinical trials. / Carsten, Christa; Chen, Pinyuen.

In: Journal of Biopharmaceutical Statistics, 20.02.2016, p. 1-7.

Research output: Contribution to journalArticle

@article{5b9d9956c2dd4b43abc579aab2434541,
title = "Curtailed two-stage matched pairs design in double-arm Phase II clinical trials",
abstract = "This article proposes a curtailed two-stage matched pairs design to shorten the drug development process in Phase II clinical trials for which there are two arms, a treatment arm and a control arm, and the primary goal being to test whether the treatment is significantly better than the control. The design presented in this article uses the inverse trinomial distribution to determine appropriate cutoff points for the termination or continuation of the trial at each stage and is best suited for trials in which there is a low success rate and the available sample size is limited, such as is the case for trials involving rare forms of cancer or other uncommon diseases.",
keywords = "Curtailed two-stage design, double-arm, expected sample size, matched pairs, Phase II clinical trial",
author = "Christa Carsten and Pinyuen Chen",
year = "2016",
month = "2",
day = "20",
doi = "10.1080/10543406.2015.1074921",
language = "English (US)",
pages = "1--7",
journal = "Journal of Biopharmaceutical Statistics",
issn = "1054-3406",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Curtailed two-stage matched pairs design in double-arm Phase II clinical trials

AU - Carsten, Christa

AU - Chen, Pinyuen

PY - 2016/2/20

Y1 - 2016/2/20

N2 - This article proposes a curtailed two-stage matched pairs design to shorten the drug development process in Phase II clinical trials for which there are two arms, a treatment arm and a control arm, and the primary goal being to test whether the treatment is significantly better than the control. The design presented in this article uses the inverse trinomial distribution to determine appropriate cutoff points for the termination or continuation of the trial at each stage and is best suited for trials in which there is a low success rate and the available sample size is limited, such as is the case for trials involving rare forms of cancer or other uncommon diseases.

AB - This article proposes a curtailed two-stage matched pairs design to shorten the drug development process in Phase II clinical trials for which there are two arms, a treatment arm and a control arm, and the primary goal being to test whether the treatment is significantly better than the control. The design presented in this article uses the inverse trinomial distribution to determine appropriate cutoff points for the termination or continuation of the trial at each stage and is best suited for trials in which there is a low success rate and the available sample size is limited, such as is the case for trials involving rare forms of cancer or other uncommon diseases.

KW - Curtailed two-stage design

KW - double-arm

KW - expected sample size

KW - matched pairs

KW - Phase II clinical trial

UR - http://www.scopus.com/inward/record.url?scp=84958749283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958749283&partnerID=8YFLogxK

U2 - 10.1080/10543406.2015.1074921

DO - 10.1080/10543406.2015.1074921

M3 - Article

SP - 1

EP - 7

JO - Journal of Biopharmaceutical Statistics

JF - Journal of Biopharmaceutical Statistics

SN - 1054-3406

ER -